Company / SG&A Expense
Baxter International SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$2.9B
FY2025
5-year range
$2.8B / $3.1B
FY2021-FY2025
Trend
-2.6%
vs FY2024
Sector context
#22 of 158
Health Care
What the data says
Baxter International's sg&a expense of $2.9B is higher than 86% of companies in the Health Care sector (FY2025). SG&A Expense has fluctuated over the past 10 years, ranging from $2.5B in FY2020 to $3.3B in FY2016.
Based on SEC 10-K filings.
$2.9B in FY2025 with a 5-year CAGR of +3.2%. Top quartile in the Health Care sector.
Improved from $3.0B to $2.9B over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -2.3%
- 5-Year CAGR
- +3.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 14% in Health CareTop 86% of 158This company $2.9B Sector average $175.9B
▼
-98.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +3.2%, indicating consistent growth.
- In FY2025, sg&a expense decreased 2.6% year-over-year.
- Ranks #22 out of 158 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2016.
Company context
Key Data Points
- Negative profit margin: -6.1%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.9B | -2.6% |
| FY2024 | $3.0B | +0.5% |
| FY2023 | $3.0B | -4.6% |
| FY2022 | $3.1B | +8.9% |
| FY2021 | $2.8B | +15.2% |
| FY2020 | $2.5B | -6.0% |
| FY2019 | $2.6B | +0.3% |
| FY2018 | $2.6B | -0.3% |
| FY2017 | $2.6B | -20.8% |
| FY2016 | $3.3B | +7.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026